CAMBRIDGE, Mass.--(BUSINESS WIRE)--ReviveMed Inc, an AI-driven drug discovery platform, today announced that CEO Dr. Leila Pirhaji has been selected as a TED Fellow, joining a class of 20 change-makers from around the world to deliver a talk on the TED stage this April in Vancouver. Dr. Pirhaji was selected in recognition of her scientific and entrepreneurial work at the intersection of artificial intelligence and biology.
“I am thrilled to share how we can use technology and artificial intelligence to discover therapeutics for diseases with unmet medical needs,” said Dr. Pirhaji. “Millions of people are currently suffering from metabolic diseases with no treatments. We are passionate about understanding how changes in the small molecules or metabolites in our body leads to the progression of these diseases, because this could be the key to developing effective therapeutics, and ultimately saving many lives.”
Dr. Pirhaji was selected for her work in the field of computational biology. Over the last 13 years, Dr. Pirhaji has explored ways to use math and computer science algorithms to understand biological systems, and her research has led her to leading academic institutes and pharmaceutical companies in Iran, Switzerland and the U.S. During her biological engineering Ph.D. at MIT, she developed a pioneering artificial intelligence (AI) platform to characterize a large set of small molecules or metabolites within the human body for drug discovery purposes. This research was published in Nature Methods and served as the foundation for ReviveMed, the company she founded to bring this technology to the market. Dr. Pirhaji and her team have since received several prestigious awards from institutions like Novartis, Bristol-Myers Squibb, MIT and Google Cloud.
“We are thrilled to announce the newest class of TED Fellows, who give voice to some of the most exciting ideas we’ve seen in the program’s 10-year history,” said TED Fellows director Shoham Arad. “The Fellows program is committed to using its resources and platform to help scale Fellows' ideas and impact, and we are so excited to have these Fellows become an integral part of our global community.”
Founded in 2009, the TED Fellows program has 472 Fellows from 96 countries, whose talks have been viewed more than 250 million times overall. In its ten-year history, the TED Fellows program has created a powerful, far-reaching network made up of scientists, doctors, activists, artists, entrepreneurs, inventors, journalists and beyond. As a TED fellow, Dr. Pirhaji will join this history-making community. Learn more about the complete list of all new 2019 TED Fellows and TED Senior Fellows at ted.com/fellows.
ReviveMed is an AI-driven drug discovery platform focused on discovering therapeutics for metabolic diseases including fatty liver diseases. ReviveMed is a pioneer in the intersection of artificial intelligence and metabolomics, located in the heart of biotech innovation in Cambridge, MA. ReviveMed uniquely overcomes the difficulties of identifying a large set of metabolites for each patient, based on the technology that ReviveMed’s founders developed at MIT and published in Nature Methods. It further translates metabolomic data into novel therapeutic insights for drug and drug response biomarker discovery. Currently, ReviveMed is collaborating with tier-one pharmaceutical companies and pursuing internal drug discovery programs. Learn more at www.revivemed.io, and follow us on Twitter, Facebook, Instagram, and LinkedIn.
About the TED Fellows program
The TED Fellows program brings together young innovators from around the world and across disciplines, who display both outstanding achievement and exemplary character, to raise international awareness of their work and maximize their impact. The program offers Fellows full participation in a TED or TEDGlobal Conference, a two-day pre-conference of workshops and activities, a Fellows Retreat, ongoing professional coaching and mentoring, dedicated PR coaching and active participation in the TED community, including the global TED Fellows network.